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In Finland, the Biobank Act entered into effect in 
2013. The primary motivation for the act is to enable 
the utilization of collected biological sample material 
for medical research. However, in order to effectively 
utilize this data, there exists a need to develop new 
technological solutions to support the collection and 
management of potentially large sets of sensitive data 
through multiple stages of processing. The cumulative 
data stored within biobanks will enable multi-
disciplinary research and new innovations. We 
propose an architecture that addresses several 
challenges involved in defining and deploying a 
biobank infrastructure including consent management, 
data management and data transfer. Our architecture 
expedites the development of this important area within 
the research and industrial communities, and enables 
the deployment of service-oriented biobanks.  
 
 
1. Introduction  
 
Biobanks are becoming an increasingly common 
method for storing large collections of biological 
samples and relevant medical data collected from 
donors who have provided consent. There exist many 
benefits in creating a locally centralized repository for 
including but not limited to allowing researchers access 
vast quantities of data that would be otherwise difficult 
to obtain from many different sources.   
Globally, many hundreds of biobanks exist. In the 
European Union, there are currently 315 active 
biobanks. Large biobanks currently in operation 
include the UK biobank, German National biobank, 
The Estonian Genome Center/The Estonian Biobank 
cohort and Danish National biobank. Currently, most 
scientific publications come from North America, 
Great Britain and Central and Southern Europe. Europe 
has a common infrastructure BBMRI-ERIC 
(Biobanking and BioMolecular resources Research 
Infrastructure-The European Research Infrastructure 
Consortium) for co-operation. [16, 21] 
The guiding principles of the Biobank Act in 
Finland (established 1.9.2013) are promotion of trust, 
equal access to data and samples, protection of privacy, 
acceleration of innovation activities and exposing 
biobank activities to public scrutiny. The primary 
motivation for this act coming to pass is to develop a 
strong biobank research infrastructure, by overcoming 
hurdles like complex collaboration networks, sensitive 
data (hard identifiers, sensitive attributes), anonymized 
data conflicting with the need to identify subjects and 
additionally to identify and satisfy the needs of 
multiple stakeholders [19]. 
In 2015 nine biobanks have been granted the right 
to operate by Valvira (National Supervisory Authority 
for Welfare and Health) in Finland: Auria biobank, 
THL biobank, Finnish Hematological Registry and 
Biobank, Helsinki Urological Biobank, Academic 
Medical Center Helsinki Biobank, Northern Finland 
Biobank Borealis, Finnish Clinical Biobank Tampere, 
Central Finland biobank and Biobank of Eastern 
Finland. The profiles of the biobanks differ from each 
other to avoid redundant effort. There are currently no 
commercial biobanks in Finland, and the existing 
infrastructures primarily offer sample management and 
consultation in marketing and sales [16]. 
Some research goals would not be feasible without 
large biobank collections and the collaboration 
between biobanks. Moreover biobanking will require a 
consistent, harmonious collection of samples and data. 
Without harmonization, the advantage of the 
collaboration and data integration to enlarge dataset 
from several biobanks is highly non-trivial [10]. This 
puts pressure also for updating the representation of 
data in already existing collections. This is not a simple 
task as biobanks can store data of many distinct types 
and employ different data models and formats. Yet, the 
various information systems must be integrated with 
other information systems to allow both internal and 
external interoperability while maintaining and 
efficient and secure environment for the data to reside. 
The purpose of this paper is to define an 
architecture for biobanks that corresponds to the 
requirements of a national architecture for biobanks 
and address the requirements for harmonization, 
national needs and regulations. Hence our research 
question: How to define an architecture for a 
biobank?. This work is based on extensive 
3469





collaboration between national actors in biobank 
domain; Finnish biobanks, software and systems 
providers, standardization organizations, hospitals and 
several other actors in the health care domain. 
The remainder of this paper is organized as follows. 
Section 2 discusses the background for this work. 
Section 3 presents our research process. Section 4 
outlines the proposed biobank architecture and Section 
5 discusses the results. Section 6 concludes this work 
summarizing the key findings.  
 
2. Background  
 
The biobank shall store collected samples (DNA, 
cell tissue etc.) and associated clinical data about the 
donors [13] in a locally centralized repository. The 
information contained within the biobank is to be made 
available for the purposes of medical research. 
Management of the data is initiated by the granting of 
consent by a donor [4]. Currently the consent or 
revocation of consent is provided in written form and 
stored [7]. Samples and relevant data are stored within 
the biobank in an encoded form. The platform should 
handle the management of the data contained within, 
so that it can be easily queried and combining results 
with auxiliary information is possible. Such data may 
include but is not limited to digitized sample material 
in the form of whole slide images that may each 
occupy multiple gigabytes on disc [8]. When a 
researcher or commercial organization expresses 
interest in the biobank data (through e.g. a national 
catalog), the data is retrieved and passed through a 
secondary round of encoding prior to being released. 
Auxiliary material is collected from other sources, if 
required. The biobank should keep various registers 
including coding registry, registry of removed codes, 
registers of samples, registers of the utilization of data, 
registers for releases and returns of data. The biobank 
information management system should also handle 
the results of operations upon this data by researchers, 
which may of an arbitrary type. 
 
2.1. National consensus 
 
The operating model of the biobanks requires 
several stakeholders to give consent, to supervise, to 
utilize services, to complement data, to provide finance 
and support, to provide services and to provide 
common methods. The biobank itself will report these 
activities, provide sample and other data, provide 
services, and give expertise to BBMRI work to find 
and establish common national methods. International 
work goes through BBMRI in BBMRI-ERIC. National 
Institute for Health and Welfare in Finland (THL) is a 
national coordinator of BBMRI work, but also acts in 
many other roles. [22]  
The Ministry of Health and Social Affairs (STM) 
has initiated a national effort on describing the 
architecture for biobanks in Finland. The purpose is to 
describe the operational environment as well as to 
define requirements for efficient operation. The short-
term goal is to enable uniform operating guidelines for 
biobanks so that there may exist a national-level 
common infrastructure. This is an important window of 
opportunity for Finnish research and for international 
research networking. [22] 
The framework suggests that certain services be 
handled in a common way. The management of 
consents that are granted or revoked by donors should 
reside in a single service. The transfers and material 
transfer agreements should also be similarly handled. 
Furthermore, it is important that the researcher can see 
the available data through an availability catalog 
database and in the second level through availability 
search service. In this regard, the complexity of the 
biobank should be abstracted away behind a single 
user-facing interface. Additionally, a coding service 
(method to separate actual identity from the stored 
data) is planned to be common. Biobanks shall thus 
integrate these national services into their own 
operational environment. [22] 
In the national framework, certain parties have been 
suggested to assume control over these services. The 
consent register and event register could be part of 
Kanta (National Archive of Health Information) and 
OmaKanta (portal to personal medical records and 
electronic prescriptions). Responsibility of the coding 
service is not yet clear. It is important that the coding 
service is consistent across several biobanks when data 
is combined. The possibility to search all available data 
is a necessity to establish a national biobank operation 
and could arise from work in BBMRI. Consequently 
there should exist a common or at minimum 
interoperable information system. This is preceded by 
a definition of a reliable method to identify researchers 
and to manage access rights to the services. [22, 15] 
The biobank is to store data indefinitely or until 
consent for the data is revoked. The structure of the 
basic data and logic for linking should therefore be 
simple. Moreover, the interfaces for data collection and 
release should be well defined and easy to use.  
 
2.2. Core components of the biobank IT 
infrastructure 
  
Functional components of the biobank 
infrastructure may be divided into four core 
components (cf. [1]): 1) Consent tracking; 2) Sample 
management; 3) Laboratory processing; 4) Facilitating 
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access to data and samples. Forthcoming European 
General Data Protection Regulation (GDPR) requires 
that informed, explicit consent is necessary [4].  
When the samples and related metadata are 
processed for inclusion into the biobank, coding, 
anonymization and pseudonymization are required. 
Sample management includes sample processing, 
storage and inventory management. High-speed, large 
storage solutions are required (up to 100 TB per year) 
[17, 11]. An integral part of the biobank IT 
infrastructure is the database for samples and related 
metadata. Laboratory processing includes the analysis 
and processing of biological samples. Powerful 
processing capabilities are required for potential 
concurrent analysis of large image files that may be up 
to several gigabytes in size. Finally, the distribution of 
data and samples to researchers has to be managed. 
This requires sufficient information capabilities [15] 
including availability services like catalogues to 
deliver the data to users. This occurs either through 
online viewing or other data distribution methods. 
Further components are e.g. firewalls and other 
security measures that increase the security, integrity 
and redundancy of data. The definition of public and 
private APIs is also necessary to enable applications 
and services. Standardization and harmonization are 
also necessary, as there are differences in operating 
procedures between biobanks [2]. This can be due to 
local policies or technologies, and transparency is 
needed to make the data re-usable [2]. 
 
3. Research process  
 
The research consisted of studying several 
organizations in related fields with the aim of defining 
the architecture. Several workshops with various 
organizations were arranged. Approaching our research 
question in an iterative manner was viewed as optimal 
as there were multiple actors and different domains 
involved. The concept was still evolving such that 
there were no clear views on how a biobank could be 
defined or constructed. Additionally, the requirements 
and environment experienced a constant flux as the 
laws and regulations were being crafted and refined. 
Table 1 presents the organizations and different 
sources that participated the definition of the biobank 
architecture. The organizations were chosen such that 
they all could provide relevant data related to the 
research question. Experts and managers from different 
organizational levels were involved. Examples of input 





Table 1. Biobank actors. 
Source Input 
Valvira -Biobank permission 
-Supervision 
Sample donor, person -Consent 
-Samples 
KELA (The Social Insurance 
Institution of Finland) 
-Information systems service  
THL -Architecture 
-BBMRI-ERIC: Obligations 
BBMRI -Common methods 
Registry -Source data 
Service provider -Service 
Health care units -Sample and data 
-Support services 
Research -Sample and data 
National ethical board  -Reports 
STM -National biobank overall architecture 
 
Building the outcome iteratively allowed us to see 
the results, gather feedback and further improve our 
design. This was continued until we were able to draw 
the architecture presented in this paper. The intention 
was to define an architecture that is not dependent on 
specific vendors or components and may be modified 
and scaled to meet the future demands. The research 
process (Fig. 1) followed the guidelines presented by 
Runeson and Höst [18], in an iterative manner.  
 
 
Figure 1. Research process [18]. 
 
In the design phase, the objectives and research 
problem in addition to the theoretical background were 
determined. Following this, the research methods and 
sources were chosen. The preparation phase included 
defining the topics to discuss with data sources, 
defining the data sources, and agreeing on the 
procedures. During the data collection phase, data were 
gathered from data sources via numerous workshops 
and discussion (first-degree data). This included 
collecting archive material such as process descriptions 
and workflows provided by the data sources (second-
degree data) and the literature (third-degree data). 
Memorandums were made from workshops and 
discussions and summarized for all researchers. The 
main discussion points, relevant questions and 
interesting themes were then extracted from the data 
and analyzed further. Data analysis provided further 
topics for the following workshops and discussions. An 
understanding was gradually built as the process 
continued. Then, based on our understanding, the 
initial architecture was sketched. This was then 
discussed between representatives of participating 
organizations. Several discussions and workshops were 
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arranged at the companies for the participating 
organizations to go through the findings and results. 
Feedback from the workshops was incorporated in the 
analysis. The results of this process are reported here. 
 
4. Proposed biobank architecture  
 
The complete topology has been separated into 
multiple independent domains, grouping related 
services. It is possible to assign ownership 
responsibilities to each domain and modify the 
physical or logical mechanics to meet real-world 
requirements while ensuring topological coherence. 
This is achieved by strictly defining the input and 
output interfaces described for each domain. This 
architecture presents the topology of the biobank 
infrastructure and does not specify specific 
implementation details. The overall architecture is 
designed such that each component exists in an 
isolated environment communicating with other 
components through encrypted sockets. The overall 
architecture with an example on service scenario for 
both donor and recipient is shown in the Fig. 2. 
 
 
Figure 2. Overall architecture for the biobank. 
 
Isolation is achieved at the component level 
through dedicated virtual machines and at the domain 
level by physical hardware. This approach allows for 
simplified scalability and allows new services to be 
included in the system. Additionally, by isolating 
components, the impact of security breaches may be 
localized and better contained. Similarly, isolating 
components allows for stricter definitions of valid 
traffic and thus potentially malicious or erroneous 
traffic can be better identified. Furthermore, this 
approach enables a heterogeneous collection of 
components from multiple vendors to coexist, 
communicating using open standard protocols and data 
formats. This aids in ensuring the future relevance of 
the biobank in constantly evolving medical and 
technological environments. 
The hospital domain (Fig. 3)	 represents a 
collection of systems and devices upon which the data 
from consenting donors is stored. New data sources 
may be added within this domain as permission is 
granted or access is deemed feasible. Access to each 
data source is granted independently and that access is 
governed through a formal request procedure.  
Additionally, the success of the biobank 
infrastructure may encourage the inclusion of data sets 
that are of a format that have not yet been considered, 
such new data inserted into the biobank from the 
research community. As a consequence, the biobank 
infrastructure has been designed to be agnostic of data 
formats and instead seeks to allow data from multiple 
sources to co-exist through a harmonization process. 
 
 
Figure 3. The hospital domain. 
 
The collection domain (Fig. 4) represents a series 
of systems that are utilized in the amalgamation of the 
various data sources in the hospital domain in addition 
to consent information. The data contained within this 
domain is a complete representation of the original 
data. An additional benefit of maintaining this 
collection of data is that currently the requirements for 
encoding and obfuscating the datasets in addition to 
what may be included is not currently standardized and 
may change over time. By having an exact 
representation of the original data it is possible to 
ensure the continued compliance to data safety 




Figure 4. The collection domain. 
 
This is designed as such so that in the event of a 
catastrophic failure, the biobank may utilize the data 
stored within this section to re-build the data set, 
bypassing production hospital systems. This is required 
as access to the hospital domain systems is limited. 
Prior to forwarding a data set to the encoding server for 
pseudonymization, a transfer delta is computed of the 
data contained within the collection server. This 
transfer delta is obtained by combining the unique, 
relevant fields from each table in the database that have 
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been created or modified after the last batch transfer 
and for which consent exits.  
The collection domain requires the use of a 
database running on a dedicated hardware instance that 
is directly connected only to the encoding domain and 
will expose an encrypted network attached storage 
device for each hospital domain system with unique 
keys that is then pulled into the collection server. This 
database shall mirror the table structure of each 
database that exists as a valid source for the biobank. 
Data will undergo a harmonization process to ensure 
that incoming data is in a format suitable for inclusion 
into the biobank while maintaining the original 
structure. By mirroring the table structure of the source 
data, it is possible to ensure that data is not discarded 
unnecessarily and all transformations upon the source 
data may be computed non-destructively. 
Consent data is transmitted to the consent register, 
which is stored within the collection domain. After 
consent has been registered, a sample ID created from 
the original data is stored within the collection domain 
with a Boolean value indicating the status of consent. 
The encoding domain (Fig. 5) is responsible for 
ensuring that any personally identifying information is 
sanitized from the original data set prior to inclusion in 
the biobank primary repository. 
 
 
Figure 5. The encoding domain. 
 
The encoding domain is additionally responsible 
for building up a code registry, which keeps a record of 
personally identifying information and primary codes. 
For anonymizing data a variety of methods are 
available, like encryption, hashing, substitution or 
removal of personally identifiable information. We 
approach this as follows. Data entering the encoding 
server from the collection domain is passed through a 
sanitization process generating a unique sample 
identifier through a one-way mapping process. 
Additionally, fields within the data set may be altered 
to prevent exposing identifying information. Upon 
completion of the sanitization process, a unique 
identifier for each sample processed is transmitted to 
the code registry over a secure connection. This 
identifier enables authorized personnel to map between 
the original samples and the pseudonymized biobank 
samples.  
The staging domain (Fig. 6) facilitates the 
physical separation of the systems containing sensitive, 
personally identifying information and the sanitized 
data within the biobank primary repository. This 
domain comprises only a network attached storage 
device that may be mounted by only a single device at 
any point in time.  
Since it is required that the regions containing 
sensitive information be entirely separated from the 
regions that can be considered general-access, it is 
necessary for there to exist an additional separating 
region. In this staging region, the encoding service 
briefly mounts a remote storage drive and deposits the 
encoded data prior to disconnecting. The repository 
domain then mounts the drive to fetch the deposited 
data. Data deposited in the staging area by the 
encoding domain shall be encrypted with the public 
key of the repository domain and shall have execution 
permissions disabled on the data. Upon successful 
mounting, the device shall lock access to the drive until 
such time that the connected client disconnects. It is 
required that only one device be connected to the 
staging domain at a given time to ensure that there 
does not exist a possibility for malicious traffic to flow 
between the regions. 
 
 
Figure 6. The staging domain. 
 
The repository domain (Fig. 7) serves as the 
primary repository for the data that will be utilized for 
research purposes. The primary components of the 
biobank are a query server upon which resides a 
relational database allowing for queries of arbitrary 
complexity. Additionally, there exists a storage 
allocation containing non-textual data sets that may 
incur a significant storage, bandwidth or computational 
cost. Within this domain, there exists a requirement for 
the primary database and storage server to have a high-
availability and be reasonably fault-tolerant. In Fig. 7 
the structure of the repository domain is described, 
showing the path of data from the staging domain into 
the primary biobank database. The access mechanisms 
through which the service domain may communicate 
with the biobank primary repository are also detailed. 
For data received from the staging domain, it is 
necessary to verify the source of the data and 
determine that the data is well formed. To do so, an 
integration server is utilized to read the retrieved data 
and prepare it for inclusion into the primary biobank 
database. To effectively serve arbitrary queries into the 
database, it is necessary that within the service domain, 
a structured request is constructed using prepared 
statements and have any potentially malicious 
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statements nullified prior to entering the repository 
domain. Upon receiving a well-formed request 
statement, the query server shall collect the requested 
data with textual data represented as a JSON or 
similarly trivially readable file for effective parsing by 
a web client in the service domain. Additionally, other 
non-textual data shall be packaged and transmitted 
over a secure connection to complete the request. 
 
 
Figure 7. The repository domain. 
 
The service domain (Fig. 8) comprises the set of 
systems that serve as a boundary layer between the 
biobank systems and the formation of requests for 
biobank data. In the service domain, an extensible set 
of services can be developed facilitating multiple use-
cases for accessing the biobank allowing for scalable 
research efforts. In the basic case, there shall exist an 
interface into the biobank served over a secure HTTPS 
connection that shall facilitate requesting science data 
from within the biobank to the recipient. Prior to 
releasing data to external systems, a second round of 
data encoding is performed to fully sanitize any data 
that is made available from within the biobank. 
 
 
Figure 8. The service domain. 
 
The use of an interface served over HTTPS, 
utilizing modern and open standards allows for there to 
not exist a dependency on any one particular type of 
environment from which the request is formed. This 
platform-agnostic approach ensures that the biobank is 
accessible from many types of research environments. 
Additionally, there is a possibility for a rapid 
deployment of security updates in the event that 
vulnerability is discovered. The safety of the data 
contained within the primary repository and preceding 
domains is paramount and thus there exists a 
requirement that modifications can be rapidly deployed 
to all data request origin points. 
 
5. Discussion  
 
Identified challenges can be divided into three 
categories: 1) Consent management and 
anonymization; 2) Sample management and 
harmonization; 3) Distribution of data and samples. In 
addition, there are technological challenges that exist 
in each category. Large-scale infrastructures have an 
inherent complexity in their design, construction and 
management [21]. Consequently, implementation costs 
for large-scale digital pathology environment may be 
high [11]. Moreover, technological limitations and 
insufficient performance of commercial solutions are 
identified [11]. With our architecture we aim to address 
all these challenges. 
Data transfer requirements are considerable in 
digital biobanks. For example a typical tissue sample 
of 12x20 mm in size with 20x magnification can result 
an image many gigabytes in size. Thus, the transfer of 
images will require sufficient bandwidth. It is however 
possible to compress the images without introducing 
artifacts that measurably impact the quality of the 
image. The impact of compression must be validated 
prior to conducting an analysis on the data, as different 
compression methods may have different effects on 
image quality. [5] 
Furthermore, the number of large files induces a 
storage burden. Rojo [17] estimated that about 100 TB 
of storage per year is needed to store the data generated 
in a pathology department in a 500 beds hospital. 
Hence, the storage investment might be substantial. In 
any case, there must be carefully planned storage and 
backup systems. Tiered storage systems are suggested 
to mitigate the high costs of storage [11]. 
Interoperability and integration issues are likely to 
arise. There are several components and services in a 
biobank environment that must be interoperable and 
there are various standards and specifications for 
enabling an interface [12]. Thus, data harmonization 
must be addressed carefully. 
 
5.1. Consent management and anonymization 
 
Given the sensitive nature of the data contained 
within a biobank, it is paramount that biobanks protect 
the confidentiality of the data according to national and 
international laws and regulations. Currently there is 
no real consensus regarding managing consents in 
biobanks [3]. However, the forthcoming GDPR covers 
e.g. consents and data protection.  
The permission of the biobank to handle samples 
and related information is based upon the existence of 
consent. The Biobank Act requires written consent, 
with a signature. There is a right for the sample donor 
to deny and revoke the consent to the use of samples at 
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any time. Despite the national work integrating the 
consent management as part of the Kanta system, the 
biobank itself has to maintain a register of the 
consents. The Biobank Act defines that the donor has a 
right to know about the information stored in the 
biobank and any usage of said data (log files). 
Additionally, donors may elect to get information 
about the research done with their data. The initial 
requirements considering biobank consent 
management with OmaKanta have been defined in 
Kääriä et al. [9]. One technical issue is the integration 
of the local system to the forthcoming implementation 
of the national system as well as the integration to 
basic processes of the particular processing 
environment. 
Protecting the privacy of genetic information 
requires that the data or samples are coded or 
anonymized. One issue influencing the information 
systems is the coding used to pseudonymize the social 
security numbers. According to the law, the sample 
and related information has to be coded. The 
information must be kept separate from the coding key 
and the information system must make possible the 
secure storage, usage and follow up of the information. 
The coding service is defined to include services 
related to the separate storage of the identifying 
information and samples and the management of the 
related coded information. One portion of this is code 
registry, which enables associating sample and 
information registry data to the information in the 
consent registry. The coding service is utilized for 
generating secondary codes when releasing data. If 
systems do not agree on a compatible coding space, 
and hinder or make it more difficult to collect data 
from multiple biobanks for research there shall exist a 
greater complexity in attaining a coherent and unified 
national biobank infrastructure [22].  
 
5.1.1. Our solution to consent management and 
anonymization. Input from multiple sources is 
amalgamated and sanitized prior to inclusion in the 
biobank database. Consent for a data set is verified, the 
data is encoded to remove personally identifying 
information and any file format specific data is 
disassembled into raw meta data and image data prior 
to being sent into the biobank database. The collection 
domain receives data from sources including, but not 
limited to, hospital databases providing data in a 
trivially readable format by means of either a direct 
connection or by manual file transfer, medical scanners 
producing large image files, existing image data 
retrieved from PACS servers within the hospital or 
data that is manually entered. The sanitization process 
for images shall require significant memory if multiple 
requests are to be handled simultaneously. However, 
since the encoding domain functions as a filter in the 
data path, it is not required to store additional copies of 
the data passed to it. This data shall exist in its original 
form in the collection domain and in its encoded form 
in the repository domain. 
 
5.2. Sample management and harmonization 
 
Qpati is one example of a hospital information 
management system. It specially designed for the 
utilization in pathology departments. The system stores 
the sample number, sample types and other relevant 
information concerning the samples and has several 
device interfaces. For example, it has the capability to 
produce barcodes or QR codes for physical samples. 
The Qpati system enables analysis, management of 
information, storing diagnoses and has in addition 
connections to other patient information systems [14]. 
The Qpati system has been in use in several hospitals 
in Finland and updates on the system have gradually 
been added, consequently different hospitals may have 
a different version in use. Different hospitals may also 
use different clinical terms [15]. 
Harmonization is one of the critical enablers for 
achieving a greater effective utilization from biobanks. 
Harmonization and sustainability are the two key 
strategic priorities to increase interoperability among 
international biobank infrastructures [6]. 
Harmonization at a national level is also necessary and 
it is the first step towards global interoperability. 
Standard operating procedures and harmonization are 
required during sample collection, processing and 
storage. Access to comprehensive and well-organized 
collections of samples is needed as well as the 
associated clinical and research data which in turn 
require harmonization of operational procedures and 
best practices [6]. Interoperability is essential in 
enabling the exchange of data and samples. BBMRI is 
also one effort towards harmonization and 
development of common research infrastructures. 
There exist multiple choices to implement an 
infrastructure that facilities these constraints. Currently 
there exist commercial products like BC Platforms 
(http://bcplatforms.com/), which handle basic biobank 
functionality (code, consent, transfer, log registers 
sample data management, links to availability 
database, data integration), and enable application 
development through API interfaces. Similarly, basic 
functionality could be achieved with non-commercial 
alternatives like Samwise, which is an in house sample 
management and information management system used 
at FIMM (the Institute for Molecular Medicine 
Finland) and THL biobank or Core (Code, Consent and 
Transfer Registry application by FIMM). This option is 
under consideration by several biobanks. However, 
3475
  
differences in storing blood sample information and the 
needs for pathological sample data vary. Similarly, the 
operational environments vary so the system is far 
from compliance with existing interfaces and hospital 
information systems. However, there is an option to 
construct a system from first principles relevant to the 
requirements of a particular biobank. The advantage of 
this is the possibility to devise innovative solutions and 
not rely on a single vendor.  
 
5.2.1. Our solution to information management. We 
elected to derive a system based upon the requirements 
of a biobank storing pathological samples. In our 
solution, the primary database in the biobank will 
contain all the relevant data for which a patient has 
consented to the inclusion of in addition to all data 
generated during use of the biobank. Images and other 
non-textual data will be referenced by a URI, which 
can be retrieved from the data storage. It is intended 
that this database be scalable to accommodate future 
growth. Thus, efforts will be made from the 
commencement of this research project to facilitate 
distributed database schemas. 
The hardware for the primary database must have a 
high availability and fault tolerance as time in which 
the system is not functioning is to be minimized. The 
data stored in the primary biobank database shall be 
primarily textual data, which will not incur significant 
storage cost relative to the image data stored 
separately. However, due to the vast number of records 
that may be queried, in addition to requests including 
image data, there will be a high memory utilization on 
this system. It is necessary to include solid-state 
storage for optimal disc access times when components 
may not be fully retained in memory.  
The storage of large images and additional data sets 
that may be of an arbitrary type are to be stored in a 
scalable array of attached storage devices. This 
separation from the primary database is beneficial as it 
permits a faster storage mechanism on the primary 
database server for many queries that do not contain 
image data as it is cost prohibitive to create a large 
storage array of solid-state drives. The consequence of 
this approach is that there will exist latency for the 
real-time visualization of images. However there exist 
benefits in the trivial scalability of the storage system 
and the ease of creating a distributed file system to aid 
in redundancy. To effectively store the large data sets 
present within the biobank in addition to facilitating 
the scaling of storage capacities to meet future demand, 
external storage servers are required. The servers will 
be accessible only by the primary database and will 
appear as a single unified file system. Effective 
redundancy strategies and data protection strategies 
must be determined carefully.  
Considering harmonization, the information stored 
in the Qpati system plays an important role. The aim is 
to harmonize usage of terminology by creating a 
common term catalog. Accordingly, using Qpati data 
provided by different hospitals, all data is converted 
into the same code spaces. Automatic conversion using 
UMLS can provide conversion of SNOMED (The 
Systematized Nomenclature of Medicine) medical 
terms into the same code space to some extent. 
However, the process needs manual verification for 
ensuring the quality of the output. Frequency lists are 
created representing the usage of terminology (parsed 
from Qpati data) to evaluate how the terms are used 
and which variables are more important for automatic 
analysis. This harmonization of terminology shall act 
as the basis for the build-up of a common availability 
service enabling queries over multiple biobanks. 
Moreover, tools to provide frequency lists can be 
useful also in the actual availability service.  
 
5.3. Facilitating access to data and samples 
 
There is a strong need to ensure confidentiality of 
medical data in biobanks. Such requirements are set by 
the European Data Protection Directive (Directive 
95/46/EC) and in the forthcoming GDPR. Use of 
samples and data are subject to strict coding 
requirements unless otherwise consented to [19]. 
BBMRI.fi (Finnish national node of BBMRI) attempts 
to address these issues with an infrastructure that 
provides various IT tools; such as tools for ensuring 
security like KITE availability service 
(https://kite.fimm.fi/), which supports authentication 
and REMS (Data request and access approval system). 
For facilitating access to data and samples, a 
national availability service shall be set up. The 
primary goal of a national availability service is to 
provide researchers a method to easily locate 
appropriate data/samples for research [20]. 
The definition of biobank research is broader than 
the definition of scientific research in other Finnish 
laws. Biobank research is defined as research, which 
takes advantage of samples and the related information 
to improve health, to understand disease mechanisms 
and the development of services and practices in health 
and patient care. The law additionally includes applied 
research targeting products and services [20]. 
Furthermore, facilitating access to cumulative 
digitized data enables e.g. identifying trajectories of 
healthy aging and developing new strategies for public 
health, including new tools for diagnostics, treatment 
and intervention. It will also create possibilities for 




5.3.1 Our solution to data distribution. Our solution 
offers a web server–a boundary layer that facilitates 
interaction with the biobank database. In this layer, a 
web interface hosted on a physical server will allow 
users e.g. to query the biobank database, visualize 
image data and obtain statistics on the available data 
set. It is recommended that this layer not receive 
incoming connections from the internet. This boundary 
layer consists of a single physical server that requires 
the ability to handle multiple concurrent connections 
and service multiple requests. This layer will 
experience significant bandwidth consumption during 
the visualization of the image data and so there exists a 
large memory requirement. All communications 
between any two parts of the system in addition to all 
storage is to be fully encrypted. 
The data catalog is utilized for finding information 
about the data that is currently available. This should 
be presented to the researchers in commonly agreed 
format and with appropriate links to the biobank for 
further information if available and methods to search 
over included metadata. In order to provide efficient 
services, an information pool with appropriate 
information collected by biobanks that could be 
queried in one location would be optimal. Information 
stored in Qpati is just one example of existing 
information. In addition hospitals store information in 
various other systems. The three-step process of 
forming a national availability service is described in 
[20]. Work on Qpati data harmonization will open up 
the issue by providing scripts and tools for the future. 
The catalog and availability service is planned to have 
a web-interface, and the already available KITE system 
is a good candidate as a platform.  
The biobanks have defined basic protocols for 
handling research permits in their applications to 
Valvira. A scientific board, potentially involving an 
ethics committee and external consultants, processes 
each research application. Then a written contract is 
made with the background organization of the 
applicant. The researcher receives the samples and 
related information in a coded format. Challenges exist 
regarding the confidentiality (what kind of register 
information can be obtained about the donor) and on 
practices and policies of research results returning to 
the biobank as this data should be made available for 
future research as well as to the donors.  
 
6. Conclusions  
 
A biobank is a system that amalgamates data from 
multiple sources to facilitate multidisciplinary research 
by providing a repository for a large number of 
samples and any associated data. Data stored within the 
biobank is considered to exist in perpetuity and as a 
consequence, it is necessary to define an architecture 
that utilizes the knowledge of multiple fields spanning 
science, technology and medicine to ensure the 
relevance of the system in the future. The architecture 
presented in this document strives to define a simple 
architecture that can be easily scaled to meet the future 
demands of the biobank. 
The primary considerations in this architecture are 
toward the safety and security of the data and services 
in addition to ensuring that the internal details of the 
system may be abstracted away when the system is 
utilized in production. The correctness of the system 
and the data stored within it is paramount. 
For data to be included into the biobank, consent 
must be obtained and stored. Upon such time that 
consent is received, the data for which consent is 
granted is stored within the biobank and becomes 
available to be queried. The data may contain textual 
data only, or it may contain image data that may be 
multiple gigabytes in size. 
Furthermore, there exist many challenges in 
implementing a biobank architecture. The system shall 
contain highly sensitive data with strict legal guidelines 
on how it may be stored and accessed. Implementation 
must necessarily enforce the separation of components 
both through the use of virtual machines hosting each 
component and the use of physical hardware 
boundaries to delimit regions of varying data 
sensitivity. Additionally, all communication between 
any two components and any storage upon which data 
resides are to be fully encrypted. While currently many 
of these challenges remain as open questions with 
regards to specific implementation details, this 
architecture attempts to account for a volatile set of 
requirements. 
The results should interest both academics and 
practitioners as they provide an architecture for a 
biobank infrastructure. The study also lays the 
groundwork for further scholarly inquiry including 
validating the findings in practice. For practitioners, 
this work provides a better understanding of the key 
challenges to be addressed and it defines real needs of 
various stakeholders. 
There is still a need for further work. For example 
the quantity of data potentially handled in biobanks 
creates many research problems regarding how to best 
index and access the data in a multi-user environment. 
Additionally, there exists an opportunity for further 
study into the effective integration and interoperability 
of biobanks at both a national and international level. 
Solutions to these problems will require further studies. 
Finally, implementing our architecture and deploying a 
functioning biobank environment should follow in 
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